Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Patent
1996-01-11
1999-07-06
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
4241601, 435 7021, 4351722, 4353391, 530370, 530379, 53038835, 5303894, 5303919, A61K 39395, A61K 3940, A61K 3942, A61K 3944
Patent
active
059194570
ABSTRACT:
Immunoconjugates comprising the monoclonal antibody TXU-5/B53 linked to pokeweed antiviral protein or bioactive subunits thereof are provided which are effective for the treatment of mammalian HIV infection.
REFERENCES:
Piatier-Tonneau, D., et al., "Characterization of 18 Worshop anti-CD4 mAb: epitope mapping to CD4 mutants and effects on CD4-HLA class II interaction", Leukocyte Typing, 476-479, (1995).
Torbett, B.E., et al., "hu-PBL-SCID Mice: A Model for Human Immune Function, AIDS, and Lymphomagenesis", Immunological Reviews, 1991, No. 124, 139-164, (1991).
Mosier, D.E., et al., "Human Immunodeficiency Virus Infection of Human-PBL-SCID Mice", Science, vol. 251, 791-794, (Feb. 15, 1991).
McCune, J.M., et al., "Suppression of HIV Infection in AZT-Treated SCID-hu Mice", Science, vol. 247, 564-566, (Feb. 2, 1990).
Stirpe, F., et al., "Ribosome-inactivating proteins up to date", FEBS Letters, vol. 195, No. 1,2, 1-8, (Jan. 20, 1986).
Stirpe, F., et al., "Ribosome-inactivating Proteins from Plants: Present status and future prospects", Bio/Technology, vol. 10, 405-412, (Apr., 1992).
Dore, J.M., et al., "Mutations dissociating the inhibitory activity of the pokeweed antiviral protein on Eukaryote translation and Escherichia coli growth", Nucleic Acids Research, vol. 21, No. 18, 4200-4205, (Sep. 11, 1993).
Irvin, J.D., "Pokeweed antiviral protein", Pharmacology & Therapeutics, vol. 21, No. 3, 371-387, (1983).
Lord, M.J., et al., "Ribosome inactivating proteins of plants", Cell Biology, vol. 2, 15-22, (1991).
Haynes: Scientific and Social Issues of . . . : Science: vol. 260: pp. 1279-1286, 1993.
Haynes, et al.: Update on the issues of HIV. . . : the Finnish Medical Society DUODECIM, Ann Med: 28: pp. 39-41, 1996.
Dahlgleish, et al., Nature, 312, 763, (1984).
Erice, et al., Clinical Infectious Diseases, 18, 149, (1994).
Fauci, Clin. Res., 32, 491, (1985).
Fauci, Science, 239, 617, (1988).
Fischl, et al., Ann. Intern. Med., 112, 727, (1990).
Fischl, et al., New Engl. J. Med., 317, 185, (1987).
Ho, et al., New Engl. J. Med., 317, 278, (1987).
Lasky, et al., Science, 233, 209, (1986).
St. Clair, et al., Science, 253, 1557, (1991).
Venkatesan, Science, 241, 1481-1485, (1988).
Volberding, et al., N. Engl. J. Med., 322, 941, (1990).
Yarchoan, et al., Blood, 78, 859, (1991).
Myers, D.E., et al., "Production of a pokeweed antiviral protein (PAP)-containing imjunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form fo human clinical tials", Jounal of Immunological Methods, 136, pp. 221-238, (199).
Uckun, F.M., et al., "Effective Immunochemotherapy of CALLA+Cu+ Human Pre-B Acute lymphoblastic leukemia in mince with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide", Blood, vol. 79, No. 12, pp. 3116-3129, (Jun. 15, 1992).
Fox: No winners againt AIDS: Bio/Tech: vol. 12: p. 128, Feb. 1994.
Cohen: Jitters jeopardize AIDS vaccine trails: Science: vol. 12: pp. 980-981, Nov. 1993.
Zarling, et al. : Inhibition of HIV replication . . . : Nature:. vol. 347: pp. 92-95, Sep. 1990.
Piatier-Tonneau, et al. : Characterisatic. of 18 workshop anti-CD4 mAb: . . . : Leukocyte Typ. V: pp. 476-479, 1995.
Irvin, et al. : Pokeweed antiviral protein . . . : Pharm. Ther.: vol. 55: pp. 279-302, 1992.
Zarling, et al. : Inhibition of HIV replication in seropositive patients . . . : Int. J. Immuno.: vol. 13, Suppl. 1: pp. 63-68, 1991. Duplicate.
Erice, et al. : Anti-human immundeficiency virus . . . :Anti mich. Ag. Chemother. : vol. 37, No. 4: pp. 835-838, 1993. Duplicate.
Eisenschenk Frank C.
Nelson Brett
Regents of the University of Minnesota
LandOfFree
TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-897297